Determination of cefixime trihydrate in human plasma from a developed orodispersible tablet using a validated RP-HPLC method
Acta Chromatographica · 29.05.2026
DOI: 10.1556/1326.2026.01505 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Chromatographica, erschienen am 29.05.2026. Verfasst von Syed Adnan Rizvi und 1 weiteren Autor:innen. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cefixime is a third-generation oral cephalosporin commonly used to treat infections of the upper and lower respiratory tract, middle ear, sinuses, urinary tract, and gonorrhea. Currently, various dosage forms of cefixime are available on the market, produced by many local and multinational pharmaceutical companies. This study aims to systematically develop and optimize cefixime trihydrate orodispersible tablets (400 mg) using a meticulous Design of Experiments approach and to evaluate their in vivo pharmacokinetics by a validated RP-HPLC method. A central composite design was employed, with croscarmellose and mannitol as the input variables. The effects of these variables were assessed on tablet breaking force (hardness), disintegration time, and cumulative drug release. The optimization was performed using desirability, both numerically and graphically, and the optimized formulation was subsequently tested for accelerated stability. A robust RP-HPLC method was validated for plasma linearity, accuracy, and precision, and applied for the pharmacokinetic evaluation of cefixime in the optimized formulation. Micromeritics results showed variation in flowability and compressibility across the formulation blends, ranging from excellent to slightly poor characteristics. The tablet hardness was greatly affected by the relative amount of mannitol, which also improved drug dissolution by enhancing drug wettability in the medium. Higher levels of croscarmellose significantly reduced tablet disintegration time. Numerical and graphical optimization was conducted to find a formulation with suitable hardness, minimal disintegration time, and maximum dissolution within 15 min. Fourier transform infrared spectra and differential scanning calorimetry thermograms indicated no chemical interactions, and stability studies predicted a shelf life of approximately 33.36 months for the optimized formulation. The validated method showed linearity in human plasma ( R 2 = 0.9991) and acceptable accuracy and precision. In vivo pharmacokinetic evaluation showed improved performance compared to existing immediate-release formulations, with increased C max , decreased T max , and higher AUC. Overall, this study suggests that high-dose orodispersible tablets can be systematically developed without trial and error by using an appropriate design space, enabling the industry to create robust, well-designed formulations that align with ICH quality guidelines.
Zitieren
APA
Rizvi, S. A., & Khaliq, S. A. (2026). Determination of cefixime trihydrate in human plasma from a developed orodispersible tablet using a validated RP-HPLC method. Acta Chromatographica. https://doi.org/10.1556/1326.2026.01505
Vancouver
Rizvi SA, Khaliq SA. Determination of cefixime trihydrate in human plasma from a developed orodispersible tablet using a validated RP-HPLC method. Acta Chromatographica. 2026. doi:10.1556/1326.2026.01505
BibTeX
@article{Rizvi2026,
author = {Rizvi, Syed Adnan and Khaliq, Sheikh Abdul},
title = {Determination of cefixime trihydrate in human plasma from a developed orodispersible tablet using a validated RP-HPLC method},
journal = {Acta Chromatographica},
year = {2026},
doi = {10.1556/1326.2026.01505}
}
EUVIMED